Equity
€839,344 ▲ 10.9%
XTRAPHARMA paid out €60,000 in dividends. That is 42% of the 2025 profit.
XTRAPHARMA
Overview
Lifetime
5 annual accounts with figures on one time axispeak €459,743 (2022)
€228,023▲ 43.8%
peak €343,031 (2022)
€142,634▲ 70.7%
peak €839,344 (2025)
€839,344▲ 10.9%
€1.3m▼ 7.7%
Board2 names since 2020
1 directorNaoufal ESSRIFI
Documentsfilings and deeds
29-07-20262 days before the deadline
2025abbreviated format
Gross margin from €158,591 to €228,023Result from €83,557 to €142,634Dividend €60,000Cash from €83,879 to €266,028
Key points
from the 2025 annual accountsChecked score
87
Excellent
Financially stronger than 56% of small companies in wholesale trade (NACE 46)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.3% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.2% across 4,374 companies (NACE 46, small).
About 3 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 7.6%
01-2025: 10.2%▲ +2.6 percentage points vs 12-2024highest value
02-2025: 10.2%● unchanged vs 01-2025highest value
03-2025: 5.2%▼ -5.0 percentage points vs 02-2025
04-2025: 4.8%▼ -0.4 percentage points vs 03-2025
05-2025: 4.8%● unchanged vs 04-2025
06-2025: 4.7%▼ -0.1 percentage points vs 05-2025
07-2025: 4.7%● unchanged vs 06-2025
08-2025: 6.2%▲ +1.5 percentage points vs 07-2025
09-2025: 6.2%● unchanged vs 08-2025
10-2025: 6.2%● unchanged vs 09-2025
11-2025: 6.6%▲ +0.4 percentage points vs 10-2025
12-2025: 0.9%▼ -5.7 percentage points vs 11-2025
01-2026: 0.9%● unchanged vs 12-2025
02-2026: 0.9%● unchanged vs 01-2026
03-2026: 0.9%● unchanged vs 02-2026
04-2026: 0.9%● unchanged vs 03-2026
05-2026: 1.0%▲ +0.1 percentage points vs 04-2026
06-2026: 1.0%● unchanged vs 05-2026
07-2026: 1.1%▲ +0.1 percentage points vs 06-2026
08-2026: 0.3%▼ -0.8 percentage points vs 07-2026
09-2026: 0.3%● unchanged vs 08-2026
10-2026: 0.3%● unchanged vs 09-2026lowest value
11-2026: 0.3%● unchanged vs 10-2026lowest value
Financial strengthAverage
Score breakdown
raises risk
2 of the last 3 accounts late
Founded in 2020
lowers risk
Size: total assets €2.2m
Figures for financial year 2025 (filed on 29-07-2026)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, small). It does better than 45% of them on solvency, 34% on liquidity, 76% on profitability and 69% on growth.
The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 6,782 companies had the same profile as XTRAPHARMA has now. Each dot stands for 17 companies, two years later.
96.7%
were still trading
2.7%
stopped another way
0.6%
went bankrupt
That fits the bankruptcy probability of XTRAPHARMA itself: 0.3% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 6,782 companies, not a prediction for XTRAPHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €70,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 1.55 (1.44 in 2024), above the usual 1.5. Short-term debt is 61.3% and cash 12.3% of total assets. However, 61.3% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 29-07-2026, 2 days ahead of the deadline.
NBB · 5 filingsDeviation from the deadline
2025
2 days early
2024
117 days late
2023
477 days late
2022
92 days late
2021
194 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 5 accounts on average 176 days after the deadline. In the sector (NACE 46), the median for financial year 2024 was 3 days before the deadline, and 39% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 25 November (4 of the last 5 accounts filed within 119 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
10-11-2026 today31-12-2026 year end31-07-2027 deadline
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0751561839
Registered office moved from Laeken to Haren
New registered office: Rue de la paroisse 22- 1130 HAREN · Previous registered office: Avenue de versaille 20, 1020 LAEKEN · Gazette deed
Registered office moved from Etterbeek to Laeken
New registered office: Avenue de versaille 20, 1020 LAEKEN · Previous registered office: Rue Abbé Cuypers 3, 1040 Etterbeek · Gazette deed
Transfer of 100 shares from Mounir EDDAIF to Naoufal ESSRIFI
Resignation: Mounir EDDAIF (director) · Appointment: Naoufal ESSRIFI (director) · Director discharge: Mounir EDDAIF · General meeting of 15-10-2020 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| XTRAPHARMA Brussels | €2.2m | €228,023 | 38.7% | - |
| MEDIM Kruisem | €1.9m | €349,936 | 40.5% | - |
| PROTEX HEALTHCARE Roeselare | €2.8m | €324,298 | 7.6% | 1 |
| LÖWENSTEIN MEDICAL BELGIUM Blegny | €1.6m | €140,804 | -58.0% | 2.6 |
| UDental Asse | €1.4m | €375,172 | 12.2% | 5.2 |
| Biosynex Pharma Benelux Saint-Josse-ten-Noode | €2.9m | €259,103 | 57.8% | 7.2 |
| ENDOCEUTICS Brussels | €3.5m | €415,353 | 6.8% | - |
These companies have the same main activity as XTRAPHARMA: wholesale of pharmaceutical and medical goods (NACE 46460). They are comparable in size and age: total assets between €1.4m and €3.5m, founded between 2018 and 2022.
Official details
Source: KBO- Status
- Active since 28-07-2020Normal situation
- Activity
- Wholesale of pharmaceutical and medical goodsNACE 46460and 1 other
- Establishment unit
- 2.362.529.8221130 Brussels, since 15-10-2020
- Financial year end
- 31 December
- Peppol
- Reachable since 02-06-2025
Annual accounts 2025
- €228,023▲ 43.8%
- ≈ €1.2mestimated
- €142,634▲ 70.7%
- €839,344▲ 10.9%
- €2.2m▼ 1.3%
- Filing
- Filed on 29-07-2026, 2 days before the end of the filing period
Insights on XTRAPHARMA
XTRAPHARMA files the abbreviated format. That format states no turnover. The gross margin fell from €290,436 in 2021 to €228,023 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette.
Financials
Annual accounts 2025
abbreviated format, filed on 29-07-2026, 2 days before the deadline€228,023
▲ 43.8%
€192,720
▲ 52.8%
€225,072
▲ 48.9%
€174,985
▲ 61.1%
38.7%
▲ 4.3 percentage points
1.55
▲ 0.11
Money flows
no detail for 2025Balance sheet
balance sheet total €2.2m on 31-12-2025What the company ownsHow it is paid for
in euro
in euro
Position in the sector
38.7%
Higher than 46% of 9,901 companies in 2025.
1.55
Higher than 44% of 9,664 companies in 2025.
6.6%
Higher than 64% of 9,779 companies in 2025.
XTRAPHARMA
Middle half of the sector
80% of the sector
Abbreviated accounts in wholesale trade (NACE 46)
Net result: top quarter · Equity: middle half · Balance sheet total: middle half · Working capital: top quarter
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Balance sheet: assets | ||||||
20/58 |
2.2m | 2.2m | 2.8m | 1.5m | 586,785 | |
21/28 |
105,572 | 119,714 | 56,357 | 45,688 | 36,371 | |
22/27 |
98,672 | 112,814 | 49,457 | 38,788 | 29,471 | |
22 |
14,035 | 17,547 | - | - | - | |
23 |
10,265 | 14,930 | 20,299 | 28,977 | 20,318 | |
24 |
74,372 | 80,338 | 29,158 | 9,810 | 9,153 | |
28 |
6,900 | 6,900 | 6,900 | 6,900 | 6,900 | |
29/58 |
2.1m | 2.1m | 2.8m | 1.4m | 550,414 | |
3 |
443,905 | 737,458 | 742,311 | 243,034 | 37,759 | |
30/36 |
443,905 | 737,458 | 742,311 | 243,034 | - | |
37 |
- | - | - | - | 37,759 | |
40/41 |
1.3m | 1.3m | 1.8m | 1.1m | 497,751 | |
40 |
747,556 | 742,679 | 1.6m | 948,964 | 438,511 | |
41 |
597,995 | 509,512 | 244,279 | 178,449 | 59,240 | |
54/58 |
266,028 | 83,879 | 226,904 | 52,685 | 14,905 | |
490/1 |
6,391 | 1,874 | 5,525 | - | - | |
| Balance sheet: equity and liabilities | ||||||
10/49 |
2.2m | 2.2m | 2.8m | 1.5m | 586,785 | |
10/15 |
839,344 | 756,711 | 673,154 | 563,268 | 220,236 | |
10/11 |
5,000 | 5,000 | 5,000 | 5,000 | 5,000 | |
10 |
- | - | - | 5,000 | - | |
100 |
- | - | - | 30,000 | - | |
101 |
- | - | - | 25,000 | - | |
14 |
834,344 | 751,711 | 668,154 | 558,268 | 215,236 | |
17/49 |
1.3m | 1.4m | 2.2m | 905,552 | 366,548 | |
42/48 |
1.3m | 1.4m | 2.2m | 905,552 | 366,548 | |
42 |
45,326 | 49,994 | 63,000 | - | - | |
43 |
380,000 | 395,371 | 505,000 | - | - | |
430/8 |
380,000 | 395,371 | 505,000 | - | - | |
44 |
675,254 | 863,600 | 1.5m | 720,397 | 284,467 | |
440/4 |
675,254 | 863,600 | 1.5m | 720,397 | 284,467 | |
45 |
167,523 | 129,441 | 103,508 | 185,155 | 72,583 | |
450/3 |
167,523 | 129,441 | 103,508 | 185,155 | 72,583 | |
47/48 |
60,000 | - | - | - | 9,498 | |
| Income statement | ||||||
70 |
- | - | 8.6m | - | - | |
9900 |
228,023 | 158,591 | 168,943 | 459,743 | 290,436 | |
60/61 |
- | - | 8.4m | - | - | |
630 |
32,351 | 25,035 | 9,206 | 4,921 | 1,771 | |
640/8 |
2,952 | 7,053 | 11,165 | 4,858 | 795 | |
66A |
- | 376 | - | - | - | |
9901 |
192,720 | 126,126 | 148,571 | 449,964 | 287,870 | |
75/76B |
8,320 | 450 | 7 | 1,627 | 60 | |
75 |
8,320 | 450 | 7 | 1,627 | 60 | |
65/66B |
20,325 | 17,086 | 7,761 | 638 | 276 | |
65 |
20,325 | 17,086 | 7,761 | 638 | 276 | |
9903 |
180,715 | 109,490 | 140,817 | 450,953 | 287,653 | |
67/77 |
38,082 | 25,933 | 30,931 | 107,922 | 72,417 | |
9904 |
142,634 | 83,557 | 109,886 | 343,031 | 215,236 | |
9905 |
142,634 | 83,557 | 109,886 | 343,031 | 215,236 | |
| Appropriation of the result | ||||||
9906 |
894,344 | 751,711 | 668,154 | 558,268 | 215,236 | |
14P |
751,711 | 668,154 | 558,268 | 215,236 | - | |
694/7 |
60,000 | - | - | - | - | |
694 |
60,000 | - | - | - | - | |
| Document | ||||||
The notes to these accounts have 6 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the accounts filed with the NBB.
Source: Annual accounts 2025 at the NBB, filed on 29-07-2026.
Filings
each dot is a set of accounts, on the day it reached the National Bank| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | abbreviated format | 29-07-2026 | 2026-00346675 | |
| 31-12-2024 | full format | 25-11-2025 | 2025-00570223 | |
| 31-12-2023 | micro format | 20-11-2025 | 2025-00568653 | |
| 31-12-2022 | full format | 31-10-2023 | 2023-00499872 | |
| 31-12-2021 | micro format | 10-02-2023 | 2023-00026120 |
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| 225,072 | 151,162 | 157,778 | 454,886 | 289,641 | ||
| 174,985 | 108,592 | 119,092 | 347,952 | 217,007 | ||
| 18,209 | 88,392 | 19,877 | 14,238 | 37,036 | ||
| 182,148 | -143,025 | 174,219 | 37,781 | - | ||
| 733,772 | 636,997 | 616,796 | 517,580 | 183,866 | ||
| - | - | 1.7% | - | - | ||
| 38.7% | 34.5% | 23.7% | 38.3% | 37.5% | ||
| 1.55 | 1.44 | 1.28 | 1.57 | 1.50 | ||
| 1.22 | 0.93 | 0.94 | 1.30 | 1.40 | ||
| 1.58 | 1.90 | 3.22 | 1.61 | 1.66 | ||
| 17.0% | 11.0% | 16.3% | 60.9% | 97.7% | ||
| 6.6% | 3.8% | 3.9% | 23.4% | 36.7% | ||
| 11.07 | 8.85 | 20.33 | over 100 | over 100 | ||
| - | - | 67 days | - | - | ||
| - | - | 65 days | - | - |
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Investments
fixed assets acquired| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tangible fixed assets | €18,209 | €88,392 | €19,877 | €14,238 | €30,136 |
| Financial fixed assets | - | - | - | - | €6,900 |
| €32,351 | €25,035 | €9,206 | €4,921 | €1,771 |
Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)
Insights on XTRAPHARMA
The operating result for 2025 is 53% higher than in 2024 and the highest since 2022. It is a recovery after the fall in 2024.
Debt's share of the balance-sheet total falls from 65.5% to 61.3%. Equity is higher and debt is lower.
Large changes and their cause
- 2023 Net result -68% on 2022. The accounts now follow the micro format, last year the full format.
- 2022 Net result +59% on 2021. The accounts now follow the full format, last year the micro format.
Board & ownership
Board
1 director, no change since October 2020Director
appointed by deed of 13-11-2020
listed in the 2025 annual accounts, filed on 29-07-2026
- Signing authorityThe articles say who may bind the company, for example by signing a contract.
- Each director alonedeed of 30-07-2020
Mandates through the years
2 names, the dashed line is todayNaoufal ESSRIFI
Director
Director
Mounir EDDAIF
Director
Director
BoardEarlier
Mandates as a list
- Naoufal ESSRIFI
- Director, appointed by deed of 13-11-2020, still in office
- Mounir EDDAIF
- Director, appointed by deed of 30-07-2020, until 15-10-2020
Control
Capital
- Contribution
- €5,000
- Shares
- 100
- Contribution per share
- €50
- Equity per share
- €8,393 in 2025
- Source
- 2025 annual accounts
Articles of association
deed of 30-07-2020 (in French)- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- Fourth Friday of June at 10:00
- Statutory auditorA statutory auditor is a registered auditor who checks the annual accounts. Small companies need not have one.
- No statutory auditor
Shareholders
Stated in the deed
deed of 13-11-2020 ↗
- Naoufal ESSRIFI all shares
Share transfer
deed of 13-11-2020 ↗
- Mounir EDDAIF to Naoufal ESSRIFI 100 shares
At incorporation
deed of 30-07-2020 ↗
- EDDAÏF Mounir 100 shares (100%) · €30,000 in cash
Network & group
No group
XTRAPHARMA has no parent and no holdings in its annual accounts. Naoufal ESSRIFI is the only director. XTRAPHARMA shares no director with another company.
At the same address
Parochiestraat 22, 1130 Brussels · 1 other company| YOUROPE TRADING
registered office since 07-04-2017 · founded in 2017 |
total assets €89,184 (2025) 0674.373.989 |
Timeline
Timeline
13 events since 2020Board
Capital
Filings
Financial
Establishments
Address
2020202220242026
Deadline for the 2026 accounts: 31-07-2027
2026
Annual accounts 2025 filed NBBabbreviated format · 2 days before the deadline
2025
Annual accounts 2024 filed PDFfull format · 117 days late
Annual accounts 2023 filed PDFmicro format · 477 days late
Registered in the Peppol Directory Reachable for e-invoices through 0208:0751561839
2023
Annual accounts 2022 filed PDFfull format · 92 days late
Registered office moved from Laeken to HarenNew registered office: Rue de la paroisse 22- 1130 HAREN · Previous registered office: Avenue de versaille 20, 1020 LAEKEN1 point ▸
- Registered-office move, Rue de la paroisse 22- 1130 HAREN
- The deed holds 1 more point.
Annual accounts 2021 filed PDFmicro format · 194 days late
2022
Highest result from 2021 to 2025 net €343,031 ▲59.4% The operating result of €449,964 and the net result of €343,031 are both a record.
Equity above €500,000 equity €563,268 ▲156% With a profit in every financial year since 2021, equity grows to €563,268.
2021
Registered office moved from Etterbeek to LaekenNew registered office: Avenue de versaille 20, 1020 LAEKEN · Previous registered office: Rue Abbé Cuypers 3, 1040 Etterbeek1 point ▸
- Registered-office move, Avenue de versaille 20, 1020 LAEKEN
- The deed holds 1 more point.
2020
Transfer of 100 shares from Mounir EDDAIF to Naoufal ESSRIFIResignation: Mounir EDDAIF (director) · Appointment: Naoufal ESSRIFI (director) · Director discharge: Mounir EDDAIF · General meeting of 15-10-20206 points ▸
- General meeting, 15-10-2020
- Director resignation, Mounir EDDAIF
- Director discharge, Mounir EDDAIF
- Director appointment, Naoufal ESSRIFI
- Share transfer, Mounir EDDAIF → Naoufal ESSRIFI, 100 shares
- Naoufal ESSRIFI holds all the shares
- The deed holds 1 more point.
First establishment Parochiestraat 22, Brussels
IncorporationFounding capital of €30,000, 100 shares, €5,000 paid up · Founder: EDDAÏF Mounir · Appointment: EDDAÏF Mounir (director) · published on 30-07-20204 points ▸
- Founder, EDDAÏF Mounir
- Founding capital, €30,000, 100 shares
- EDDAÏF Mounir holds 100 shares
- Director appointment, EDDAÏF Mounir
- The deed holds 3 more points.
Financial milestones sit on the financial year-end date, not the filing date.
Sources: Publications in the Belgian Official GazetteFilings with the National Bank
History
XTRAPHARMA was incorporated on 28 July 2020 as a private limited company by one natural person, with a starting capital of €30,000.12 The registered office moved to Laeken in 2021 and to Haren in 2023.34 Naoufal ESSRIFI is director of the company, appointed by deed of 13-11-2020.5 Total assets rose from €586,785 in 2021 to €2.2m in 2025.6
Company details
Identity
- Enterprise number
- 0751.561.839
- VAT number
- BE 0751.561.839
- Peppol ID
- 0208:0751561839
- Other Peppol ID
- 9925:BE0751561839
- Legal form
- Private limited company
- Status
- Active, normal situation
- Founded
- 28-07-2020
- Financial year
- ends on 31 December
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- Fourth Friday of June at 10:00deed of 30-07-2020 (in French)
- Peppol
- Reachable since 02-06-2025Follow this company and you will hear the next morning if it leaves the Peppol register.
- Name
- XTRAPHARMA in French
- Entity type
- Legal entity
- Registered office clauseThe articles name the region of the registered office. The language of official documents depends on that region, among other things.
- “Région de Bruxelles-Capitale”deed of 30-07-2020 (in French)
Activities
NACEBEL 202546460
Wholesale of pharmaceutical and medical goods main activity
Codes under NACEBEL 2008
46460
Wholesale trade main activity
46180
Wholesale trade
- PurposeThe purpose describes the activities the company may carry out under its articles.
- “Le commerce sous toutes ses formes et notamment l'importation,l'exportation,l'achat et la vente en gros ou au détail,le trading,la…”deed of 30-07-2020 (in French)
7 activities
- Le commerce sous toutes ses formes et notamment l'importation,l'exportation,l'achat et la vente en gros ou au détail,le trading,la représentation et le courtage,ainsi que la fabrication,la transformation et le transport de toutes marchandises et de tous produits,et notamment de produits pharmaceutiques et para-pharmaceutiques.
- Toute activité de bureau d’études,recherches,assistance,prestations et conseils en matière de formation organisationnelle,financière,administrative,commerciale et sociale,marketing,relations publiques et de management.
- Audit,contrôle de qualité,et la distribution de produits(para)pharmaceutiques;l’évaluation,la présentation et le suivi de l’enregistrement/notifications de dossiers de produits(para)pharmaceutiques
- L’évaluation,la présentation,le suivi de prix et hausse de prix,la publicité et l’information concernant les produits(para)pharmaceutiques
- Le marketing,la vente,le développement,la distribution en Belgique et à l’étranger de produits(para)pharmaceutiques.
- Accomplir toutes opérations commerciales,industrielles,financières,mobilières ou immobilières,soit pour son compte,soit pour le compte de tiers,se rapportant directement ou indirectement à son objet ou qui seraient de nature à en faciliter directement ou indirectement,entièrement ou partiellement la réalisation.
- Exercer toutes fonctions et mandats et s’intéresser par voie d’apport,de fusion,de souscription ou de toute autres manière dans toutes autres affaires,entreprises,associations ou sociétés ayant un objet identique,analogue ou connexe au sien ou qui sont de nature à favoriser le développement de son entreprise,à lui procurer des ressources ou à faciliter l’écoulement des services et produits.
Registered office and establishments
1 establishment| Establishment | Since | Unit number |
|---|---|---|
| Parochiestraat 22 registered office 1130 Brussels | 15-10-2020 | 2.362.529.822 |
2 former offices
- Avenue de versaille 20, 1020 Laeken until 01-03-2023 · deed of 23-02-2023
- Rue Abbé Cuypers 3, 1040 Etterbeek until 20-05-2021 · deed of 05-07-2021
Buildings and parcels at the address
- Ground area
- 608 m²
- Buildings
- 231 m²
- Volume, LiDAR
- 1,904 m³
- Tallest building
- 12.4 m
Buildings to scale, each on its own parcel
Parcels
| Cadastral parcel | Area | Buildings | Height / floors |
|---|---|---|---|
| 21821B0318/00D002 | 608 m² | 1 · 231 m² | 12.4 m · 3 |